Benzinga's Top Upgrades, Downgrades For May 5, 2020

Upgrades

  • SunTrust Robinson Humphrey upgraded the stock for Adverum Biotechnologies Inc ADVM from Hold to Buy. Adverum Biotechnologies earned ($0.29) in the fourth quarter, compared to ($0.25) in the year-ago quarter. The stock has a 52-week-high of $16.81 and a 52-week-low of $4.96. Adverum Biotechnologies's stock last closed at $13.73 per share.
  • BMO Capital upgraded the stock for L Brands Inc LB from Market Perform to Outperform. For the fourth quarter, L Brands had an EPS of $1.88, compared to year-ago quarter EPS of $2.14. The stock has a 52-week-high of $28.02 and a 52-week-low of $8.00. L Brands's stock last closed at $12.05 per share.
  • For Skyworks Solutions Inc SWKS, Charter Equity upgraded the stock from Market Perform to Market Outperform. In the second quarter, Skyworks Solutions showed an EPS of $1.34, compared to $1.47 from the year-ago quarter. The stock has a 52-week-high of $128.48 and a 52-week-low of $66.29. Skyworks Solutions's stock last closed at $99.61 per share.
  • For BioCryst Pharmaceuticals Inc BCRX, Barclays upgraded the stock from Equal-Weight to Overweight. For the fourth quarter, BioCryst Pharmaceuticals had an EPS of ($0.02), compared to year-ago quarter EPS of ($0.25). The stock has a 52-week-high of $8.15 and a 52-week-low of $1.38. BioCryst Pharmaceuticals's stock last closed at $3.93 per share.
  • For Chegg Inc CHGG, Raymond James upgraded the stock from Market Perform to Outperform. For the first quarter, Chegg had an EPS of $0.22, compared to year-ago quarter EPS of $0.15. The stock has a 52-week-high of $48.22 and a 52-week-low of $25.89. Chegg's stock last closed at $43.85 per share.
  • Atlantic Equities upgraded the stock for First Republic Bank FRC from Underweight to Neutral. First Republic Bank earned $1.20 in the first quarter, compared to $1.26 in the year-ago quarter. The stock has a 52-week-high of $122.34 and a 52-week-low of $70.06. First Republic Bank's stock last closed at $98.93 per share.
  • Stifel changed the rating for Cutera Inc CUTR from Hold to Buy. Cutera earned $0.14 in the fourth quarter, compared to ($0.11) in the year-ago quarter. The stock has a 52-week-high of $39.15 and a 52-week-low of $9.07. Cutera's stock last closed at $12.90 per share.

 

Downgrades

  • For Stemline Therapeutics Inc STML, Ladenburg Thalmann downgraded the stock from Buy to Neutral. For the fourth quarter, Stemline Therapeutics had an EPS of ($0.38), compared to year-ago quarter EPS of ($0.92). The stock has a 52-week-high of $18.22 and a 52-week-low of $3.21. Stemline Therapeutics's stock last closed at $12.11 per share.
  • B of A Securities changed the rating for Tyson Foods Inc TSN from Buy to Neutral. For the second quarter, Tyson Foods had an EPS of $0.77, compared to year-ago quarter EPS of $1.20. The stock has a 52-week-high of $94.24 and a 52-week-low of $42.57. Tyson Foods's stock last closed at $55.33 per share.
  • Craig-Hallum changed the rating for Varonis Systems Inc VRNS from Buy to Hold. Varonis Systems earned ($0.56) in the first quarter, compared to ($0.38) in the year-ago quarter. The stock has a 52-week-high of $93.24 and a 52-week-low of $48.95. Varonis Systems's stock last closed at $64.64 per share.
  • B. Riley FBR changed the rating for Cars.com Inc CARS from Buy to Neutral. In the fourth quarter, Cars.com showed an EPS of $0.63, compared to $0.50 from the year-ago quarter. The stock has a 52-week-high of $23.08 and a 52-week-low of $3.25. Cars.com's stock last closed at $4.92 per share.
  • Deutsche Bank downgraded the stock for Builders FirstSource Inc BLDR from Buy to Hold. For the first quarter, Builders FirstSource had an EPS of $0.34, compared to year-ago quarter EPS of $0.34. The stock has a 52-week-high of $28.43 and a 52-week-low of $9.00. Builders FirstSource's stock last closed at $16.84 per share.
  • For Five9 Inc FIVN, Roth Capital downgraded the stock from Buy to Neutral. For the first quarter, Five9 had an EPS of $0.17, compared to year-ago quarter EPS of $0.16. The stock has a 52-week-high of $99.96 and a 52-week-low of $46.09. Five9's stock last closed at $95.88 per share.
  • Baird downgraded the stock for Owens & Minor Inc OMI from Outperform to Neutral. For the fourth quarter, Owens & Minor had an EPS of $0.24, compared to year-ago quarter EPS of $0.09. The stock has a 52-week-high of $9.69 and a 52-week-low of $2.43. Owens & Minor's stock last closed at $8.03 per share.
  • Atlantic Equities changed the rating for Wells Fargo & Co WFC from Neutral to Underweight. In the first quarter, Wells Fargo showed an EPS of $0.80, compared to $1.20 from the year-ago quarter. The stock has a 52-week-high of $54.75 and a 52-week-low of $25.11. Wells Fargo's stock last closed at $27.36 per share.
  • For ONEOK Inc OKE, Credit Suisse downgraded the stock from Outperform to Neutral. In the first quarter, ONEOK showed an EPS of $0.83, compared to $0.81 from the year-ago quarter. The stock has a 52-week-high of $78.48 and a 52-week-low of $12.16. ONEOK's stock last closed at $29.19 per share.

 

Initiations

  • Canaccord Genuity initiated coverage on DraftKings Inc DKNG with a Buy rating. The price target for DraftKings is set at $25.00. The stock has a 52-week-high of $22.50 and a 52-week-low of $18.00. DraftKings's stock last closed at $20.99 per share.
  • With a rating of Equal-Weight, Barclays initiated coverage on Blueprint Medicines Corp BPMC. The price target is set at $59.00 for Blueprint Medicines. For the fourth quarter, Blueprint Medicines had an EPS of ($1.35), compared to year-ago quarter EPS of ($1.83). The stock has a 52-week-high of $102.98 and a 52-week-low of $43.29. Blueprint Medicines's stock last closed at $58.13 per share.
  • With a rating of Sell, Rosenblatt initiated coverage on Salesforce.com Inc CRM. The price target is set at $120.00 for Salesforce.com. Salesforce.com earned $0.66 in the fourth quarter, compared to $0.58 in the year-ago quarter. The stock has a 52-week-high of $195.72 and a 52-week-low of $115.29. Salesforce.com's stock last closed at $161.50 per share.
  • Chardan Capital initiated coverage on Madrigal Pharmaceuticals Inc MDGL with a Buy rating. The price target for Madrigal Pharmaceuticals is set at $205.00. Interestingly, in the fourth quarter, Madrigal Pharmaceuticals's EPS was ($1.80). The stock has a 52-week-high of $121.20 and a 52-week-low of $56.82. Madrigal Pharmaceuticals's stock last closed at $87.50 per share.
  • Mizuho initiated coverage on Cytokinetics Inc CYTK with a Buy rating. The price target for Cytokinetics is set at $31.00. In the fourth quarter, Cytokinetics showed an EPS of ($0.52), compared to ($0.48) from the year-ago quarter. The stock has a 52-week-high of $16.96 and a 52-week-low of $7.72. Cytokinetics's stock last closed at $15.17 per share.
  • Chardan Capital initiated coverage on Viking Therapeutics Inc VKTX with a Buy rating. The price target for Viking Therapeutics is set at $15.00. Viking Therapeutics earned ($0.13) in the first quarter, compared to ($0.07) in the year-ago quarter. The stock has a 52-week-high of $8.92 and a 52-week-low of $3.26. Viking Therapeutics's stock last closed at $6.34 per share.
  • Barclays initiated coverage on Kura Oncology Inc KURA with an Overweight rating. The price target for Kura Oncology is set at $24.00. For the first quarter, Kura Oncology had an EPS of ($0.42), compared to year-ago quarter EPS of ($0.37). The stock has a 52-week-high of $21.42 and a 52-week-low of $6.35. Kura Oncology's stock last closed at $14.70 per share.
  • Rosenblatt initiated coverage on Workday Inc WDAY with a Sell rating. The price target for Workday is set at $110.00. For the fourth quarter, Workday had an EPS of $0.50, compared to year-ago quarter EPS of $0.41. The stock has a 52-week-high of $226.83 and a 52-week-low of $107.75. Workday's stock last closed at $148.47 per share.
  • Barclays initiated coverage on Immunomedics Inc IMMU with an Overweight rating. The price target for Immunomedics is set at $40.00. In the second quarter, Immunomedics showed an EPS of ($0.50), compared to ($0.50) from the year-ago quarter. The stock has a 52-week-high of $31.71 and a 52-week-low of $8.80. Immunomedics's stock last closed at $31.68 per share.
  • Barclays initiated coverage on Replimune Group Inc REPL with an Overweight rating. The price target for Replimune Group is set at $21.00. For the third quarter, Replimune Group had an EPS of ($0.46), compared to year-ago quarter EPS of ($0.24). The stock has a 52-week-high of $21.50 and a 52-week-low of $8.58. Replimune Group's stock last closed at $15.93 per share.
  • Barclays initiated coverage on SpringWorks Therapeutics Inc SWTX with an Overweight rating. The price target for SpringWorks Therapeutics is set at $48.00. Interestingly, in the fourth quarter, SpringWorks Therapeutics's EPS was ($0.39). The stock has a 52-week-high of $43.90 and a 52-week-low of $17.02. SpringWorks Therapeutics's stock last closed at $30.35 per share.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: UpgradesDowngradesInitiationIntraday UpdateAnalyst RatingsInitiationstop upgrades
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!